Co-Win Ventures, a prominent venture capital firm founded in 2009 with the brand spirit rooted in “Kaifeng” (southeast wind symbolizing nourishment for all things and great love, from The Book of Songs), focuses on TMT and healthcare sectors. We manage 19 RMB funds (9 angel funds, 10 growth funds) and 3 USD funds, with total AUM reaching RMB 7.7 billion.Adopting a “Farming Model”, Co-Win builds our own vertical industrial chain ecosystems with over 90% of portfolios derived directly from industrial references or existing portfolio connections. We mainly focus on early-stage investments, and we are the first institutional investor in more than 80% of our portfolios. Notable cases include InnoLight (global optical transceiver leader) and Cytek Biosciences (NASDAQ-listed flow cytometer pioneer).Boasting a 30-member elite team (all investment staff with STEM backgrounds) and led by seasoned partners like Ben Zhao and Xin Huang, Co-Win has won over 70 awards since 2015, including consistent recognition in Preqin’s Most Consistent Top-Performing Venture Capital Fund Managers (All Vintages) rankings—named to the list in 2021, 2022, and 2024, with standout rankings of No. 1 in 2022 and No. 4 in 2024. We aim to be the preferred investor for outstanding high-tech entrepreneurs, with a vision of "In China, For Global".